Kiniksa Pharmaceuticals Ltd (KNSA)vsTeva Pharma Industries Ltd ADR (TEVA)
KNSA
Kiniksa Pharmaceuticals Ltd
$76.27
-0.27%
HEALTHCARE · Cap: $6.13B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+2.04%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 1959% more annual revenue ($17.32B vs $840.85M). KNSA leads profitability with a 9.6% profit margin vs 4.1%. TEVA trades at a lower P/E of 61.3x. KNSA earns a higher WallStSmart Score of 53/100 (C-).
KNSA
Buy53
out of 100
Grade: C-
TEVA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$202.69
Current Price
$76.27
$126.42 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.4% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 30.4% YoY
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Trading at 9.1x book value
Premium valuation, high expectations priced in
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity, EPS Growth. Revenue growth of 55.4% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : KNSA
The primary concerns for KNSA are Price/Book, P/E Ratio. A P/E of 79.3x leaves little room for execution misses.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.87 — expect wider price swings.
KNSA is growing revenue faster at 55.4% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
KNSA scores higher overall (53/100 vs 49/100) and 55.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?